Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.


READ STATEMENTS


THIS WEEKS' PUBLICATIONS ON COVID-19 & PSORIASIS

No abstract
The global pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging. Various cutaneous manifestations have been observed in patients with SARS-CoV-2 infection, yet exacerbations of psoriasis have been reported sporadically. Acrodermatitis continua of Hallopeau (ACH) is an uncommon, sterile pustular dermatosis involving one or more digits. In some rare cases, ACH may evolve into generalized pustular psoriasis...
No abstract
No abstract
CONCLUSION: It is particularly crucial to tailor psoriasis care to individual needs in order to protect the physical and mental well-being of patients during the pandemic.

VIEW ALL ON PUBMED

RECOURCES FROM OUR INDUSTRY PARTNERS

 AbbVie
Amgen
Novartis
UCB

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK